Case Comprehensive Cancer Center

Real World Data Shows Impact of Immunotherapy in Populations Underrepresented in Clinical Trials, According to JNCCN Study

Retrieved on: 
Monday, December 11, 2023
Case Comprehensive Cancer Center, Assistant, Associate, Research, Safety, NCCN, Progression-free survival, Thymic carcinoma, White, National Comprehensive Cancer Network, Disease, Insurance, Patient, Pembrolizumab, Lung cancer, BMI, ECOG, MPH, Survival, Doctor of Philosophy, Immunotherapy, Chemotherapy, NSCLC, Birth control, Medical imaging, Pharmaceutical industry, Medicine, MD, Oncology

PLYMOUTH MEETING, Pa., Dec. 11, 2023 /PRNewswire/ -- New research in the December 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds patients treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance. The clinical investigators focused on patients in under-represented groups who were typically less likely to be included in the immunotherapy clinical trials that have been conducted to date. They analyzed results from 248 patients treated with pembrolizumab over a 9-year period between January 1, 2013 and June 1, 2022, with non-Hispanic Black, Hispanic, and Non-Hispanic White patients each accounting for an approximately equal percentage. Median overall survival was 16.8 to 26.3 months, similar to results previously reported in large prospective clinical trials.

Key Points: 
  • The clinical investigators focused on patients in under-represented groups who were typically less likely to be included in the immunotherapy clinical trials that have been conducted to date.
  • Median overall survival was 16.8 to 26.3 months, similar to results previously reported in large prospective clinical trials.
  • This study could change how we take care of patients and plan future lung cancer studies to better include all patients.
  • "There is a clear need for future studies to include underrepresented patient groups in clinical trials to validate these findings and to better guide clinical practice."

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Friday, August 18, 2023
Co-leaders of the Scottish Green Party, Cleveland Clinic, Code, Case Comprehensive Cancer Center, Clinical trial, SNO, Molecular medicine, Tokyo Stock Exchange, Case Western Reserve University School of Medicine, Poster, Standard Market Design, Pharmaceutical industry, Tobacco, Glioblastoma

LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.

Key Points: 
  • LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.
  • The poster will be presented by MediciNova’s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.
  • The presentation details are as follows:

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

Retrieved on: 
Friday, August 4, 2023
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, HU, Ruxolitinib, Medical Affairs Bureau, Senior, Hydroxycarbamide, Life imprisonment, Ropeginterferon alfa-2b, Case Comprehensive Cancer Center, Quality of life, National Comprehensive Cancer Network, Quality-adjusted life year, Journal of Comparative Effectiveness Research, Polycythemia vera, PV, MS, NCCN, QALY, Journal, Peginterferon alfa-2a, Journal of the National Comprehensive Cancer Network, Polycythemia, Patient, HIV disease progression rates, Risk, Phlebotomy, Treatment, Hematology, Mortality, TES, Myeloproliferative neoplasm, Safety, News, MPN, Pharmaceutical industry, MD

The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.

Key Points: 
  • The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.
  • Cost effectiveness was demonstrated in a modeled population including both low- and high-risk patients receiving first- or second-line treatment with ropeginterferon alfa-2b-njft.
  • Findings from the study conclude ropeginterferon alfa-2b-njft is a cost-effective treatment option for a broad range of patients with PV, including both low- and high-risk patients and patients with and without prior cytoreductive treatment with hydroxyurea.
  • “Ropeginterferon alfa-2b-njft has demonstrated safety and efficacy in studies including both low- and high-risk patients and patients with and without prior cytoreductive treatment with HU.

University Hospitals Seidman Cancer Center selects RayStation

Retrieved on: 
Wednesday, January 4, 2023
Photon, Proton therapy, National Cancer Institute, Patient, Case Comprehensive Cancer Center, RaySearch Laboratories, SRS, DRS, Nasdaq Stockholm, SBRT, Health, University Hospitals Cleveland Medical Center, Vincent, Partnership, IMRT, Proton, Safety, Deep learning, Karolinska Institute, Hospital, Carbon, Helium, Workplace, Physics, HDR, Brachytherapy, Ion, TCS, Case, Radiation therapy, OIS, OAS, TPS, Research, Cancer, Electron, Medical imaging, Pharmaceutical industry, Varian, Elekta

STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, in the USA, has placed an order in December 2022 and chosen to transition to RayStation®* as its primary treatment planning system.

Key Points: 
  • STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, in the USA, has placed an order in December 2022 and chosen to transition to RayStation®* as its primary treatment planning system.
  • University Hospitals Seidman Cancer Center's Department of Radiation Oncology has rapidly transformed into an internationally recognized center of excellence.
  • UH Seidman Cancer Center is part of the Case Comprehensive Cancer Center, one of the nation's leading academic and research institutions.
  • Cancer services are provided by University Hospitals Seidman Cancer Center which is part of the National Cancer Institute-designated Case Comprehensive Cancer Center (the USA's highest designation).

Flexjet Partners with University Hospitals to Transport Pet Pals Facility Dogs to Their New Home

Retrieved on: 
Tuesday, November 29, 2022
Other Transport, Aerospace, Manufacturing, Retail, Air, Transport, Pets, Other Professional Services, Oncology, Hospitals, Luxury, Consumer, Professional Services, General Health, Health, Other Travel, Transportation, Travel, Loki, Diamond, ICAO, Transport, Pet Pals, Blue, Toxicity, University of Oxford, Sikorsky S-76, Charitable organization, Technion – Israel Institute of Technology, Case Comprehensive Cancer Center, Level, Hospital, Embraer Phenom 300, Travel medicine, Cuyahoga County Airport, PETS, Dog, Caregiver, Patient, Travel, University Hospitals Cleveland Medical Center, Animal, Gulf Stream, University, Gulfstream IV, Partnership, Golden Retriever, OH, NYSE, Male, Level 2, Bombardier, News, PetSmart, Lakeview Cabin Collection, PetSmart Charities, NCI, Hermitage Volunteer Service, U.S. News & World Report, Embraer, Multimedia, Female, Gulfstream G650, Case Western Reserve University School of Medicine, Northeast Ohio Medical University, UH, Child, Woman, Medicine, Airline, Labrador Retriever, Flexjet

Flexjet, Inc. , a global leader in subscription-based private aviation, is expanding its longstanding relationship with University Hospitals (UH) by supporting the Pet Pals Program .

Key Points: 
  • Flexjet, Inc. , a global leader in subscription-based private aviation, is expanding its longstanding relationship with University Hospitals (UH) by supporting the Pet Pals Program .
  • View the full release here: https://www.businesswire.com/news/home/20221129005649/en/
    There are only 150 facility dogs with this highly specialized training working at hospitals across the country.
  • These special dogs live with hospital staff often a doctor or a nurse and will work a 40-hour work week alongside them.
  • Pet Pals is a 501c3 nonprofit organization and relies on donations to cover the costs of the dogs, their training, transportation, etc.

Oncology Expert, Dr. Nathan Pennell of the Cleveland Clinic Taussig Cancer Institute, Joins Vial's Oncology CRO Advisory Board

Retrieved on: 
Tuesday, November 1, 2022
Brigham and Women's Hospital, MD, Gastroenterology, Publication, EPRO, Dana–Farber Cancer Institute, CRO, Vial, Clinical research, EDC, Efficiency, Case Comprehensive Cancer Center, Cancer, Dermatology, Ophthalmology, Oncology, Journal of Oncology Practice, JAMA Oncology, College of Medicine, Digital technology, Hospital, Technology, Neurology, University, Doctor of Philosophy, Internal medicine, ESourcing Capability Model, Journal, Patient, Dana, Multimedia, Lung cancer, SAN, Fine chemical, Medical imaging, Pharmaceutical industry, Neuroscience, Medicine

SAN FRANCISCO, Nov. 1, 2022 /PRNewswire/ -- Dr. Nathan Pennell of the Cleveland Clinic Taussig Cancer Institute has joined Vial's Oncology CRO Advisory Board.

Key Points: 
  • SAN FRANCISCO, Nov. 1, 2022 /PRNewswire/ -- Dr. Nathan Pennell of the Cleveland Clinic Taussig Cancer Institute has joined Vial's Oncology CRO Advisory Board.
  • Nathan Pennell, MD, Ph.D., FASCO, is a Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute.
  • I am delighted to serve as an advisor for their Oncology CRO with the goal of helping cancer patients receive treatments sooner," said Dr. Pennell on joining Vial's scientific advisory board.
  • Vial operates across multiple therapeutic areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , and Neurology CRO ).

TRANSFORMATIONAL SUPPORT FROM MICHAEL AND GRACE DRUSINSKY WILL BENEFIT ADVANCED ORTHOPEDIC AND SPORTS MEDICINE CARE AT UNIVERSITY HOSPITALS

Retrieved on: 
Friday, October 7, 2022
University Hospitals Cleveland Medical Center, News, LinkedIn, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Life, UH, Woman, Hospital, University of Oxford, Cleveland Ballet, Patient, Sickness, Twitter, Program, Sports medicine, Cleveland Monsters, Rainbow Babies & Children's Hospital, Facebook, University Hospitals Ahuja Medical Center, Michael, Cleveland, Health, Nutritionist, Safety, Athlete, Rehabilitation, Chair, Orthopedic surgery, Technion – Israel Institute of Technology, FACS, U.S. News & World Report, Cleveland Browns, The Fellowship (Christian organization), NCI, Dentistry, Medicine, Technology, Neonatology, MD, Grace

CLEVELAND, Oct. 7, 2022 /PRNewswire/ -- Transformational support from community leaders Michael and Grace Drusinsky will benefit advanced orthopedic and sports medicine care at University Hospitals. In recognition, the system has renamed its nationally recognized sports medicine program in their honor: UH Drusinsky Sports Medicine Institute.

Key Points: 
  • CLEVELAND, Oct. 7, 2022 /PRNewswire/ --Transformational support from community leaders Michael and Grace Drusinsky will benefit advanced orthopedic and sports medicine care at University Hospitals.
  • In recognition, the system has renamed its nationally recognized sports medicine program in their honor: UH Drusinsky Sports Medicine Institute.
  • "The field of sports medicine is so unique, because it's about more than sickness or injury," said Grace Drusinsky.
  • In 2017, they established the Michael and Grace Drusinsky Chair in Orthopaedic Surgery and Sports Medicine in gratitude for care Michael received following a devastating shoulder injury.

AMERICAN HOSPITAL ASSOCIATION NAMES UNIVERSITY HOSPITALS THIS YEAR'S LEADER IN QUALITY

Retrieved on: 
Tuesday, July 12, 2022
Zero, Culture, University Hospitals Cleveland Medical Center, Hospital, Safety, Health equity, U.S. News & World Report, Quality, Technion – Israel Institute of Technology, Family, News, Northeast Ohio Medical University, Patient, Case Western Reserve University School of Medicine, University of Oxford, LinkedIn, Association, High reliability organization, American Hospital Association, CEO, Facebook, Food, Case Comprehensive Cancer Center, NCI, Language, Woman, FACS, Patient safety, Twitter, Health, Workforce, Caregiver, Behavior, AHA, Pharmaceutical industry, Medicine, Audit, MD, Technology

A multi-disciplinary committee of health care quality and patient safety experts gave UH the award based on the system's exemplary achievements. Specifically, AHA lauded UH for its maturity and approach to quality, safety and equity. The AHA prize committee believes quality is deeply embedded in UH's culture -- from the board level, to the unit level, and across all sites in the organization.

Key Points: 
  • A multi-disciplinary committee of health care quality and patient safety experts gave UH the award based on the system's exemplary achievements.
  • "University Hospitals has made outstanding contributions in elevating the quality of care they provide each day to their patients and communities throughout Northeast Ohio," said Rick Pollack, AHA's president and CEO.
  • "The important lessons learned from University Hospitals will inspire hospitals and health systems to advance care across the country."
  • The system's flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University and the Technion Israel Institute of Technology.

Edgility, Inc. Launches EdgeAi, a Breakthrough Explainable and Open-Box Artificial Intelligence to Accelerate Adoption

Retrieved on: 
Tuesday, May 24, 2022
Other Health, Software, Managed Care, General Health, Technology, Hospitals, Public Relations, Investor Relations, Communications, Practice Management, Other Technology, Health, Physical Therapy, Health, Population, Hospital, University Hospitals Cleveland Medical Center, Northeast Ohio Medical University, Case Comprehensive Cancer Center, Doctor of Philosophy, Multimedia, Patient, Investment, Woman, Explainable artificial intelligence, Logic, NCI, Information security operations center, UH, Discharge, Intelligence, Background Intelligent Transfer Service, Case Western Reserve University School of Medicine, Midcontinent Independent System Operator, Opacity, Algorithm, Culture, Facebook, Technion – Israel Institute of Technology, Human, Huddle, U.S. News & World Report, Macdonald, Machine learning, FACS, Trust, Adoption, LinkedIn, Twitter, News, University of Oxford, CEO, Medical device, Management, AI, Technology, MD

Trust in AI model predictions is paramount if care providers and administrators are to accept the decisions based on them.

Key Points: 
  • Trust in AI model predictions is paramount if care providers and administrators are to accept the decisions based on them.
  • EdgeAi generates a standard label for transparency of the prediction model, leading to better AI adoption and open-box development.
  • "In contrast to the traditional AI 'black-box,' which even the developer rarely understands, EdgeAi surfaces the logic to the end-user."
  • EdgeAi's predictions are translated into orchestrated actions and behaviors through Edgility's Smart Operations Platform, making this a closed-loop intelligence and action engine.

Sodexo and University Hospitals Expand and Extend Their Partnership

Retrieved on: 
Thursday, March 10, 2022
Northeast Ohio Medical University, Safety, Government, Volunteering, Twitter, University Hospitals Cleveland Medical Center, Partnership, Health, University of Oxford, Coffee, Instagram, RFP, Education, NCI, Quality of life, Food, UHCMC, Woman, UH, Case Comprehensive Cancer Center, Hospital, Case Western Reserve University School of Medicine, GLOBE, Technion – Israel Institute of Technology, Patient, News, Hunger, YouTube, U.S. News & World Report, CEO, LinkedIn, Medicine, Sodexo, Facebook, Technology, Health care

Sodexo is proud to be a trusted partner to University Hospitals Health System, said Stuart Winters, CEO, Healthcare, North America, Sodexo.

Key Points: 
  • Sodexo is proud to be a trusted partner to University Hospitals Health System, said Stuart Winters, CEO, Healthcare, North America, Sodexo.
  • We continue to value our partnership with Sodexo and all that they offer to University Hospitals Health System, said Tom Snowberger, Chief Administrative Officer of UH.
  • The renewed contract between Sodexo and UH anticipates an 11-year relationship, during which Sodexo will employ 180 people across six areas of service.
  • The systems flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University and the Technion Israel Institute of Technology.